Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Becton, Dickinson & Co., EBITDA calculation
US$ in millions
Based on: 10-K (filing date: 2020-11-25), 10-K (filing date: 2019-11-27), 10-K (filing date: 2018-11-21), 10-K (filing date: 2017-11-22), 10-K (filing date: 2016-11-23), 10-K (filing date: 2015-11-25).
Item | Description | The company |
---|---|---|
EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Becton, Dickinson & Co.’s EBITDA increased from 2018 to 2019 but then decreased significantly from 2019 to 2020. |
Enterprise Value to EBITDA Ratio, Current
Becton, Dickinson & Co., current EV/EBITDA calculation, comparison to benchmarks
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 89,757 |
Earnings before interest, tax, depreciation and amortization (EBITDA) | 3,667 |
Valuation Ratio | |
EV/EBITDA | 24.48 |
Benchmarks | |
EV/EBITDA, Competitors1 | |
Boston Scientific Corp. | 28.36 |
Danaher Corp. | 37.27 |
Edwards Lifesciences Corp. | 41.99 |
Intuitive Surgical Inc. | 53.08 |
Medtronic PLC | 22.09 |
Stryker Corp. | 26.92 |
Thermo Fisher Scientific Inc. | 30.23 |
UnitedHealth Group Inc. | 16.15 |
EV/EBITDA, Sector | |
Health Care Equipment & Services | 23.44 |
EV/EBITDA, Industry | |
Health Care | 18.99 |
Based on: 10-K (filing date: 2020-11-25).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Becton, Dickinson & Co., historical EV/EBITDA calculation, comparison to benchmarks
Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||
Enterprise value (EV)1 | 80,969 | 89,200 | 85,173 | 55,792 | 45,755 | 43,014 | |
Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 3,667 | 4,068 | 3,857 | 2,585 | 2,576 | 2,001 | |
Valuation Ratio | |||||||
EV/EBITDA3 | 22.08 | 21.93 | 22.08 | 21.58 | 17.76 | 21.50 | |
Benchmarks | |||||||
EV/EBITDA, Competitors4 | |||||||
Boston Scientific Corp. | — | 30.18 | 24.31 | 21.10 | 31.56 | 71.28 | |
Danaher Corp. | — | 25.23 | 18.47 | 17.93 | 17.88 | 15.88 | |
Edwards Lifesciences Corp. | — | 37.05 | 42.10 | 24.39 | 22.48 | 25.34 | |
Intuitive Surgical Inc. | — | 37.53 | 40.47 | 37.53 | 23.10 | 21.93 | |
Medtronic PLC | 17.92 | 16.01 | 13.94 | 16.32 | 15.92 | 22.94 | |
Stryker Corp. | — | 24.38 | 21.99 | 20.29 | 18.37 | 15.99 | |
Thermo Fisher Scientific Inc. | — | 19.74 | 19.41 | 20.47 | 18.21 | 15.80 | |
UnitedHealth Group Inc. | — | 13.96 | 14.04 | 13.61 | 11.48 | 9.81 | |
EV/EBITDA, Sector | |||||||
Health Care Equipment & Services | — | 19.06 | 17.85 | 17.43 | 15.78 | 16.08 | |
EV/EBITDA, Industry | |||||||
Health Care | — | 16.46 | 15.84 | 15.22 | 13.93 | 13.15 |
Based on: 10-K (filing date: 2020-11-25), 10-K (filing date: 2019-11-27), 10-K (filing date: 2018-11-21), 10-K (filing date: 2017-11-22), 10-K (filing date: 2016-11-23), 10-K (filing date: 2015-11-25).
3 2020 Calculation
EV/EBITDA = EV ÷ EBITDA
= 80,969 ÷ 3,667 = 22.08
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Becton, Dickinson & Co.’s EV/EBITDA ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 not reaching 2018 level. |